Telomere length is maintained by two known mechanisms, the activation of telomerase or alternative lengthening of telomeres (ALT). The molecular mechanisms regulating the ALT phenotype are poorly understood and it is unknown how the decision of which pathway to activate is made at the cellular level. We have shown earlier that active repression of telomerase gene expression by chromatin remodelling of the promoters is one mechanism of regulation; however, other genes and signalling networks are likely to be required to regulate telomerase and maintain the ALT phenotype. Using gene expression profiling, we have uncovered a signature of 1305 genes to distinguish telomerase-positive and ALT cell lines. By combining this with the gene expression profiles of liposarcoma tissue samples, we refined this signature to 297 genes. A network analysis of known interactions between genes within this signature revealed a regulatory signalling network consistent with a model of human telomerase reverse transcriptase (hTERT) repression in ALT cell lines and liposarcomas. This network expands on our existing knowledge of hTERT regulation and provides a platform to understand differential regulation of hTERT in different tumour types and normal tissues. We also show evidence to suggest a novel mesenchymal stem cell origin for ALT immortalization in cell lines and mesenchymal tissues.
Introduction
A central hallmark of cancer cells is their capacity for unlimited proliferation, made possible partly by telomere length maintenance. Most human tumours maintain telomeres by activating telomerase; however, in a smaller subset of tumours, maintenance occurs in the absence of telomerase through a recombinationbased mechanism termed alternative lengthening of telomeres (ALT). The ALT is characterized phenotypically by long, heterogeneous telomeres and the presence of ALT-associated promyelocytic leukaemia bodies, which contain telomeric DNA, telomere-binding proteins such as telomere repeat binding factors 1 and 2 and proteins implicated in DNA recombination and replication, including Mre11-Rad50-Nbs1 complex proteins MRE11, RAD51 and NBS (Yeager et al., 1999; Henson et al., 2002) . Association of these proteins with the ALT phenotype make them attractive as potential markers or regulators of ALT ; indeed, the MRN complex is required for ALT-associated promyelocytic leukaemia body formation and telomere maintenance in ALT cells .
Although the overall prevalence of ALT in tumours is relatively low, it is observed at high frequency in tumours of mesenchymal origin. However, the prevalence of ALT varies even within this group. About 77% of malignant fibrous histiocytomas (Henson et al., 2005) and 47-66% of osteosarcomas (Ulaner et al., 2003; Henson et al., 2005) were shown to be ALT positive, whereas 25% of glioblastoma multiforme (Hakin-Smith et al., 2003) and liposarcomas (Johnson et al., 2005; Costa et al., 2006) and no Ewing's sarcomas (Ulaner et al., 2004) showed evidence of ALT. Since the prognostic significance of ALT varies, signifying a good prognosis for patients with glioblastoma multiforme but a poor prognosis for those with liposarcoma (Costa et al., 2006; , and understanding the molecular details regulating ALT immortalization and the cell of origin may impact future diagnosis or treatment of these malignancies.
A possible explanation for the prevalence of ALT in mesenchymal malignancies is that the telomerase genes are more tightly repressed in mesenchymal tissues over those of epithelial origin (Henson et al., 2002) . We have earlier reported that both human telomerase RNA and human telomerase reverse transcriptase (hTERT) are actively repressed at the chromatin level in ALT cell lines (Atkinson et al., 2005) , suggesting forced repression of telomerase as one potential molecular mechanism promoting immortalization by ALT. However, other genes and signalling networks also regulate telomerase and may contribute to the decision of selecting ALT versus telomerase. In this study we investigate the gene expression profiles of telomerasepositive and ALT cell lines and liposarcoma tissue samples to better understand the molecular mechanisms regulating the decision to activate telomerase or ALT. In addition, we show a link between mesenchymal tumours and human mesenchymal stem cells (hMSCs) as the target cell for transformation in ALT immortalization.
Results

Gene expression analysis distinguishes telomerase and ALT cell lines
We initially investigated the presence of a telomere maintenance mechanism (TMM)-specific gene expression signature by generating expression profiles for four ALT and four telomerase-positive cell lines using Agilent whole human genome 1-colour microarrays (Agilent Technologies, Santa Clara, CA, USA). A detailed description of the quality control measures and the normalization options applied can be found in the section Materials and methods; however, boxplots show that the normalized data are equally spread and comparable between the two groups ( Figure 1a ), with virtually equal medians of 0.78 and 0.79 for ALT and telomerase-positive cell line groups, respectively.
To explore the possibility that expression of individual genes within these large profiles is responsible for defining either telomerase-positive or ALT cells, we performed Welch's analysis of variance test to look for significant differences in gene expression between the two groups (Figure 1b, left panel) . A list of 1307 probes corresponding to 1305 differentially expressed genes with a P-value of p0.05 was generated. By focussing on the expression values for individual genes within the larger 1305 gene signature, it was clear that whereas expression was high in the ALT cell lines it was low in the telomerase-positive cell lines and vice versa (Figure 2a ). Furthermore, hierarchical clustering of the cell lines on the basis of this signature helped to accurately bifurcate ALT and telomerase-positive cell lines into two separate groups (Figure 2b ), suggesting that the genes responsible for defining telomerase or ALT or those involved in regulating the decision of which TMM to activate may lie within this signature.
Clustering by using the 1305 gene signature is suggestive of a mesenchymal stem cell origin for ALT The fact that ALT is predominantly found in tumours of mesenchymal origin prompted us to investigate whether ALT is a function of the cell of transformation and whether mesenchymal stem cells could be the potential cell of origin for ALT tumours. We performed a hierarchical clustering analysis by using the 1305 gene signature to investigate any relationship between telomerase-positive, ALT and normal fibroblast cell lines, and hMSCs ( Figure 2c ). The signature helped to accurately separate telomerase-positive and ALT cell lines, normal fibroblasts, and hMSCs. However, whereas the telomerase-positive cell lines clustered together on a separate branch, the ALT cell lines, normal fibroblasts and hMSCs all clustered together. Normal fibroblasts are more directly related to hMSCs than ALT; however, fibroblasts and hMSCs are equally related to the ALT cell lines, suggesting a mesenchymal stem cell origin for ALT. This might be as predicted; however, to our knowledge, this is the first time any association between mesenchymal stem cells and ALT has been shown.
Analysis of the signature revealed several genes associated with stem cell maintenance, and self-renewal processes were differentially expressed between telomerase-positive and ALT cell lines. Four of these genes with strong differences in expression were chosen for validation by quantitative PCR (Q-PCR) ( Figure 3a ). Three of these genes were significantly upregulated in ALT cell lines and barely expressed in telomerase-positive cell lines. DSC54 is a novel mesenchymal stem cell protein for which little information exists; WNT5b is a wellknown regulator of stem cell function implicated in oncogenesis and development; MYEOV is overexpressed in myeloma and has a role in promoting invasion and proliferation; and the final gene, NSUN5, is a proliferation-associated nucleolar antigen, the deletion of which may contribute to the premature ageing effects of the developmental disorder William's syndrome. NSUN5 is significantly upregulated in telomerase-positive compared with ALT cell lines.
To further explore the link between ALT and mesenchymal stem cells, we examined the expression of these genes within a variety of normal tissues of differing embryonic origin and hMSCs. The publicly available gene expression profiles from normal fibroblasts, smooth muscle, stromal, ectoepithelial, epithelial and endothelial tissues were downloaded from the National Centre for Biotechnology Information Gene Expression Omnibus database and expression of DSC54, WNT5b and MYEOV in these tissues was compared with that of hMSC, telomerase-positive and ALT cell lines ( Figure 3b ). No comparable data were available for NSUN5, and therefore this gene could not be included in the analysis.
Consistent with the Q-PCR validation, the expression of all three genes is higher in ALT than in telomerasepositive cell lines. When comparing all the expression patterns, DSC54 is only high in ALT cell lines and hMSCs, consistent with a mesenchymal stem cell origin for ALT. In contrast, WNT5b shows varying expression across the different tissue types and cell lines, with highest expression in hMSC, ALT and mesenchymally derived tissues and lowest expression in telomerasepositive and epithelial tissues. MYEOV distinguishes ALT from telomerase-positive cell lines; however, a similar low level of expression is seen across the various other tissue types.
Refinement of the 1305 gene signature using liposarcoma gene expression improves separation of ALT and telomerase-positive liposarcomas and suggests a mesenchymal stem cell origin for ALT in this mesenchymal malignancy Liposarcomas are tumours of mesenchymal origin. In order to refine the cell line-derived signature with data from primary tumours, we analysed the power of the 1305 gene expression signature to distinguish between telomerase positive and ALT in liposarcomas. Gene expression profiles were generated for a group of 17 previously characterized liposarcoma samples, of which 9 were ALT and 8 were telomerase positive. Unsupervised clustering showed some split in the samples depending on their TMM, which was not improved when the 1305 gene signature was applied. Furthermore, hMSCs did not cluster with any liposarcoma samples, but clustered together on a separate branch (Figure 4 , compare a and b).
Although the 1305 signature does not improve clustering, the liposarcoma samples, for the most part, cluster together according to their TMM. The obvious separation between ALT and telomerase-positive tumours in the clustering diagram led us to believe that differences in gene expression exist between the two groups, although no significant differences were found. To explore this further, we used Fisher's exact test to test for any association between gene expression level and TMM. From this analysis, 8227 probes corresponding to 6719 genes were found to be significantly associated with TMM in ALT and telomerase-positive liposarcoma samples (Figure 1b , right-hand panel).
To further refine this large signature, we looked for any overlap with the 1305 gene signature determined from the cell lines previously. Of these 1305 genes, 422 genes are also present in the liposarcoma signature and therefore have a significant association with TMM in liposarcoma and cell lines. Further refinement of the signature was carried out by looking at the direction of gene expression in telomerase-positive and ALT tumours in comparison with the cell line data. In total, 297 of the 422 genes had gene expression that was comparable with the cell line data, 152 genes up in ALT and down in telomerase-positive, and 145 genes down in ALT and up in telomerase-positive ( Figure 1b , centre panel).
The hierarchical clustering of ALT and telomerasepositive liposarcoma samples using this refined 297 gene signature showed a clear separation between the two groups, with all except two ALT samples clustering on one branch and all telomerase-positive samples clustering together on a separate branch ( Figure 4c ). Furthermore, consistent with the hypothesized mesenchymal stem cell origin for ALT seen within the cell line data, hMSCs clustered with the ALT liposarcomas using this refined signature rather than as a separate group when the 1305 signature was applied (Figure 4 , compare b and c).
To further verify the refined signature, we applied it back to the cell line data for hierarchical clustering. As predicted, it accurately separated telomerase-positive from ALT cell lines (data not shown), further validating that this refined signature holds true and no power is lost by reducing gene number.
The refined 297 gene signature is involved in telomerase gene regulation and highlights lower c-MYC activity in ALT Given the ability of the refined 297 gene signature to separate liposarcomas by TMM, we hypothesized that the genes within the signature may comprise functional regulatory networks involved in aspects of TMM. To explore this, we performed network modelling using Metacore from Genego (St Joseph, MI, USA), allowing us to build a candidate network indicating possible interactions between genes from the 297 signature mined from published data. A regulatory network involving hTERT and telomeric DNA was revealed by this analysis (Figure 4d ). Expression data from the 297 gene signature were converted to fold change in ALT over telomerase positive, uploaded into Metacore analytical suite and overlaid on the direct interactions network. As can be seen from Figure 4d , by combining interactions between known signalling pathways and experimentally defined levels of expression for regulatory genes, this approach allows for predictions relating to hTERT regulation and repression in ALT cells. The hTERT expression is reduced in ALT cells and tumours in relation to telomerase-positive samples. Consistent with this, expression of E2F1, a known repressor of hTERT, is upregulated in ALT samples, whereas the expression of chromatin-modifying enzymes with roles in gene activation, such as GCN5, are downregulated in ALT, which is in agreement with the decreased association of acetylated histones and low hTERT expression in ALT cell lines as we have previously shown. Western blotting of HDAC5, PKCa and GCN5 (Figure 5a) shows that the expression differences highlighted in this network are also seen at the protein level.
The analysis also indicates that c-Myc regulation may contribute to the signature. Although c-Myc was not itself differentially expressed, 21 signature genes including hTERT are predicted transcriptional targets of c-Myc. Interestingly, most signature genes expected to be activated by c-Myc are repressed whereas those expected to be inhibited are mainly upregulated in ALT, relative to telomerase-positive samples, suggesting that c-Myc activity may be suppressed in ALT. Functional examination of c-Myc activity levels using DNA-binding activity enzyme-linked immunosorbent assays (ELISAs) confirms that this is indeed the case, as a significantly lower level of c-Myc activity is seen in the ALT cell lines (P ¼ 0.015; see Figure 5b ). Apart from hTERT, another downregulated c-Myc target that may have a role in telomere maintenance is heterogeneous nuclear ribonucleoprotein A3. It was recently shown that this gene binds the single-stranded telomere repeat in vitro, protects against nuclease activity and inhibits extension by telomerase (Huang et al., 2008) . More importantly, however, network analysis expands our understanding of TERT regulation beyond previously recognized mechanisms to new pathways upstream of those already known to be involved. Overall, this network highlights a potential mechanism of regulating the ALT phenotype through repression of hTERT and provides a platform for further expansions of regulatory mechanisms present in tissue or tumourspecific situations to enable us to understand the differential regulation of biological processes and how they vary in different tumour types and normal tissues.
Discussion
The molecular mechanisms regulating the decision to activate telomerase or ALT during tumourigenesis are currently poorly understood. We have shown earlier that lack of expression of the telomerase genes human telomerase RNA and hTERT is associated with chromatin remodelling at the promoters, suggesting that forced repression of these genes may cause the cells to utilize the ALT mechanism for immortalization (Atkinson et al., 2005) . In this study, we have used gene expression profiling of telomerase and ALT cell lines and liposarcomas to investigate other signalling pathways and networks that may be operating to control the ALT phenotype and the decision to activate telomerase or ALT for immortalization. To our knowledge, this is the first study of global gene regulation of TMM.
We uncovered a gene expression signature with the power to distinguish telomerase positive and ALT through hierarchical clustering methods in tumour cell lines. Further refinement of this signature using gene expression profiles from liposarcoma tissue samples revealed a 297 gene signature that has significant association with TMM. Although the role of these signatures in the regulation of the ALT phenotype remains to be fully investigated, we have uncovered some of the underlying biology by combining clinical samples with cell line profiles. A network analysis of interactions within the refined signature highlighted a signalling network involved in repression of hTERT in ALT liposarcoma samples and cell lines. Western blot validation of three of the molecules in the network confirmed that this pattern can also be observed at the protein level. Consistent with our earlier work (Atkinson et al., 2005; , this again points to forced repression of hTERT in ALT and may in part explain the decision to activate telomerase or ALT at the molecular level. Although hTERT expression alone is insufficient to discriminate ALT and telomerase positive in clinical samples, hTERT repression is clearly important for regulation of the ALT phenotype. This network of interactions also highlighted the potential for lower c-Myc activity in cells using the ALT mechanism. Upon direct investigation using c-Myc activity ELISAs, a lower level of c-Myc activity in ALT was confirmed. This is consistent with the fact that c-Myc is a known hTERT transcriptional activator (Hao et al., 2008) and may show a further mechanism by which the decision to activate either ALT or telomerase is influenced.
This candidate network further highlights the importance of a global analysis of gene expression. Where significant expression of one gene may be of importance in certain circumstances, it is more likely, as evidenced by this example, that small changes in a combination of genes in a signalling pathway are responsible for defining a phenotype. By investigating signalling networks on a global scale, we are better advantaged to discover the biology underlying the ALT phenotype and its regulation in mesenchymal malignancies. In addition to the hTERT regulatory network, a number of stem cell-related genes were also highlighted within the large gene signature. The possibility that the decision to activate either telomerase or ALT is made at the cellular level is an interesting hypothesis to consider. Cancer biology in many ways parallels that of stem cell biology as pathways regulating the self-renewal phenotype and replicative lifespan of stem cells are commonly deregulated in cancer. With the growing interest in stem cells as the cell of origin for certain tumours, investigating the potential origin for ALT immortality may improve our understanding of the regulation of telomere maintenance. The preponderance of ALT in mesenchymal malignancies prompted us to investigate any relationship between hMSCs and ALT or telomerasepositive cell lines and liposarcoma tissues. hMSCs are an adult stem cell population with limited replicative lifespan and no detectable telomerase activity (Zimmermann et al., 2003) , which is at least partly due to active repression of the telomerase genes at the chromatin level, similar to the situation in ALT cell lines (Serakinci et al., 2006; . However, hMSCs do not show characteristic molecular markers of ALT (Bernardo et al., 2007; Zhao et al., 2008) . It is therefore possible that hMSCs upon transformation could become either ALT or telomerase-positive tumours. There is, however, a need for accurate models of the molecular details of the decision between these two mechanisms, such as ours, before manipulation of the resulting TMM can be achieved.
Hierarchical clustering showed that the expression profile of the signature genes in hMSCs was more closely related to ALT than to telomerase-positive cell lines with the larger signature, and also to ALT liposarcomas when the refined 297 gene signature was utilized, suggesting a mesenchymal stem cell origin for ALT.
Mesenchymal stem cells are known to be potential targets for transformation in vitro. Lack of any TMM in these cells may be a tumour suppressor mechanism, as transduction with hTERT has been shown to extend their lifespan and induce neoplastic characteristics after long-term culture in vitro and tumour formation in vivo (Serakinci et al., 2004) . In addition, several studies have shown the ability of MSC to transform spontaneously after long-term culture in vitro in murine systems (Miura et al., 2006; Zhou et al., 2006) , although the situation in human systems remains unclear, with conflicting reports suggesting that the capacity for spontaneous transformation may be dependant on the tissue of origin (Rubio et al., 2005; Wang et al., 2005; Miura et al., 2006; Bernardo et al., 2007) . More recently, several studies have linked hMSCs with mesenchymal malignancies, including Ewing's sarcoma (Tirode et al., 2007; Riggi et al., 2008) and malignant fibrous histiocytoma (Matushansky et al., 2007) . Stem-like tumour-initiating cells have also been isolated from various mesenchymal tumours (Gibbs et al., 2005; Wu et al., 2007) . Taken together, these data suggest that the stem cell origin for cancer extends to mesenchymal malignancies.
Although the preponderance of ALT in mesenchymal tissues has been documented previously on numerous occasions, to our knowledge this is the first time the link to a mesenchymal stem cell origin for ALT has been made. Furthermore, this is not simply reflective of the mesenchymal origin of ALT cell lines as both the ALT and telomerase-positive liposarcoma samples are mesenchymally derived and only the ALT liposarcomas cluster with hMSCs. The significance of this association is unknown at present, but certainly warrants further investigation.
In conclusion, we have uncovered a gene expression signature capable of distinguishing telomerase-positive from ALT in cell lines and liposarcoma tissue samples. This signature contains a regulatory signalling network involving hTERT repression in ALT and is indicative of a novel hMSC origin for ALT. The results presented allow us to postulate two potential models for the target cell of origin for ALT and telomerase immortalization: either (1) two separate cells of origin exist for telomerase-positive and ALT-expressing malignancies or (2) telomerase-positive and ALT tumours arise from the same cell of origin. In the latter case, the cell of origin would be the hMSCs, whereby telomerasepositive tumours obtain molecular profiles over time that diversify them from the hMSC origin, whereas ALT tumours maintain the stem cell profile, perhaps in part through mechanisms such as repression of the telomerase genes. The data presented here favour the latter scenario; however, further investigation is required in the other tumour types known to utilize the ALT mechanism, such as glioma (Chen et al., 2006) , adrenocortical carcinoma, breast carcinoma, malignant melanoma, lung carcinoma, ovarian carcinoma (Bryan et al., 1997) and renal carcinoma (Mehle et al., 1996) . A better understanding of the regulation of TMM in the cell of origin will increase our knowledge of the biology underlying these tumour types and may highlight novel areas for therapeutic intervention.
Materials and methods
Cell lines and RNA extraction
The ALT cell lines used were SKLU (lung adenocarcinoma), SUSM1 (liver fibroblasts), KMST6 (lung fibroblasts), WI38-SV40 (SV40 immortalized lung fibroblasts), SAOS (osteosarcoma) and U2OS (osteosarcoma). Telomerase-positive cells used were C33a (cervical carcinoma), HT1080 (fibrosarcoma), A2780 (ovarian carcinoma) and 5637 (bladder carcinoma). Normal cell strains used were WI38 (normal lung fibroblasts) and IMR90 (normal lung fibroblasts). Bone marrow hMSCs were isolated as described earlier (Serakinci et al., 2006) and cultured using Dulbecco's modified Eagle's medium with low glucose plus Glutamax supplemented with 17% Hyclone fetal bovine serum (Thermo Fisher Scientific, Waltham, MA, USA) at 5% CO 2 .
RNA was extracted using the Nucleospin II RNA extraction kit (Macherey-Nagel, Duren, Germany) following the manufacturers' instructions.
Liposarcoma cases and RNA extraction
A subset of 17 liposarcoma samples (9 ALT and 8 telomerase positive) from a larger study population earlier described were used for gene expression analysis.
Frozen tissue was disrupted using a Hybaid Ribolyser (Hybaid, Teddington, UK) at a setting of 5.5 for 5 Â 10 s pulses with 30-s pauses in between and RNA was extracted using the RNeasy Lipid kit (Qiagen Inc., Hilden, Germany) as per the manufacturers' instructions.
Gene expression microarray hybridization, normalization and quality control In total, 4 ALT cell lines (WI38-SV40, KMST6, SKLU and SUSM1) and 4 telomerase-positive cell lines (A2780, C33a, HT1080 and 5637), 2 normal fibroblasts (WI38, IMR90), 4 hMSCs and 17 liposarcoma samples were examined using gene expression microarrays. Two separate RNA samples for each were amplified and labelled using the Agilent Low RNA Input Linear Amplification Kit PLUS, 1-colour and hybridized to Agilent whole human genome 4 Â 44 K gene expression arrays as per the manufacturers' instructions. Raw data were extracted from scanned images using Agilent feature extraction software (Agilent Technologies).
All array data was then imported into GeneSpring GX (version 7.3.1, Agilent Technologies) and normalised to the 50th, for cell line arrays, or 70th percentile for hMSC and liposarcoma arrays respectively to ensure equal medians across all samples. Further quality control involved filtering based on flag values where only those genes that had nonabsent flag values for at least half of the samples were included in downstream analysis. A box plot of the distribution of the resulting genome ( Figure 1a ) was plotted using Minitab version 14 (Minitab, Coventry, UK) to assess comparability of groups. Data files submitted to GEO for Public access under accession number GSE14533.
Statistical analysis, signature generation and clustering
All statistical analysis and signature generation were carried out within GeneSpring GX. The 1305 gene signature was generated from cell line expression profiles using Welch's analysis of variance with a false discovery rate of 0.05 and Benjamini and Hochberg multiple testing correction. A similar analysis in liposarcoma samples generated no results and therefore to generate the refined 297 gene signature, Fisher's exact test using a P-value of p0.05 was performed using the liposarcoma expression profiles to test for significant association of gene expression with TMM. From this analysis, 422 genes were also present within the 1305 signature. The genes that had fold-change values in the same direction for both cell line and liposarcoma data (that is, an increased or decreased expression in ALT compared with telomerase positive) were included in the refined signature.
All hierarchical clustering was performed using the Spearman's correlation, average linkage and merging branches with a similarity correlation of p0.001.
Q-PCR validation of microarray data
Expression of some genes within the 1305 signature was validated by Q-PCR using the DyNAmo Hot Star SYBR Green Kit (Finnzymes, Espoo, Finland) and Opticon 2 DNA Engine from MJ Research (Waltham, MA, USA). Primer sequences for Q-PCR validation were as follows:
MYEOVF: 5 0 -TGGGAGGACACGCAAGTT, MYEOVR: 5 0 -CCAGCAGCCAAAGCAAAG, WNT5BF: 5 0 -AGGAGG GAGGTTGTGGTT, WNT5BR: 5 0 -GAACCGTGGAGGAT GAAG, DSC54F: 5 0 -ACCCTTCTACGAAATGGA, DSC54R: 5 0 -ACTGTGGCTTATTCCCAT, NSUN5F: 5 0 -TGAGACC ACACTCAGCAG and NSUN5R: 5 0 -GAGAGGACAGGCA TCTTC.
Expression of each gene was normalized to glyceraldehyde 3-phosphate dehydrogenase as a loading control: GAPDHF: 5 0 -ACCACAGTCCATGCCATCAC, GAPDHR: 5 0 -TCCAC CACCCTGTTGCTGTA.
Analysis of public data
Normalized gene expression data for a compendium of 61 samples from various normal cell types were downloaded from the National Center for Biotechnology Information Gene Expression Omnibus (series GSE3239). Comparison with cell line and hMSC data was carried out in Microsoft Excel.
Network analysis in Metacore
Expression data from the 297 gene signature were converted to fold change in ALT over telomerase positive and uploaded into Metacore analytical suite. Network analysis was performed using the analyse network algorithm within the software.
Western blotting validation of network analysis
Fifteen micrograms of protein equivalents were separated on 10% Bis-Tris gels using NuPAGE MES running buffer (Invitrogen, Renfrewshire, UK), and then blotted onto nitrocellulose membrane (Millipore, Watford, UK) and blocked in phosphate buffered saline Tween-20 containing 5% nonfat dried milk. Membranes were probed with the following antibodies: HDAC5 rabbit polyclonal (Active Motif, Rixenstart, Belgium), PKCa rabbit polyclonal and KAT2A/GCN5 rabbit polyclonal (both from Abcam, Cambridge, UK) and secondary anti-rabbit IgG horseradish peroxidase-linked antibody (New England Biolabs UK, Hitchin, UK). After visualization, membranes were stripped of bound primary and secondary antibodies by submerging in 1% SDS and 0.2 m glycine (pH 2.5) and shaken for 1 h at room temperature, and rinsed and reblocked before probing with loading control antibody extracellular signal-regulated kinase 1 rabbit polyclonal (1:3000) (Santa Cruz Biotechnology, Heidelberg, Germany).
c-MYC DNA-binding ELISA Nuclear extracts of approximately 8 Â 10 8 cells of each of the six ALT cell lines (WI38-SV40, KMST6, SKLU, SUSM1, SAOS and U2OS) and four telomerase-positive cell lines (A2780, C33a, HT1080 and 5637) were extracted in triplicate using an Active motif nuclear extraction kit (Active Motif, Rixenstart, Belgium) as per the manufacturer's instructions. c-MYC DNA-binding ELISAs (Active Motif) were performed on three separate occasions with four technical replicates of each cell line as per the manufacturer's instructions. A standard curve of 5, 2.5, 1.25 and 0.625 ng/well recombinant c-MYC protein (Active Motif) was run on each assay to allow relative quantification. Results of all ALT and telomerase-positive cells were grouped and a t-test was carried out using Minitab (version 14).
